Form 4: Nautilus Biotechnology Director Akinsanya Acquires 45,000 Stock Options
SEC Form 4 Filing
Director Karen Akinsanya of Nautilus Biotechnology acquired 45,000 stock options on June 14, 2024, according to a recent SEC Form 4 filing.
Summary
- Karen Akinsanya, a director at Nautilus Biotechnology, Inc. (NAUT), acquired 45,000 stock options on June 14, 2024.
- The options have an exercise price of $2.56.
- The options vest monthly over a year, contingent on Akinsanya's continuous service as a 'Service Provider' as defined in the company's 2021 Equity Incentive Plan.
- The options expire on June 14, 2034.
Sentiment
Score: 6
Explanation: The sentiment is neutral. The document simply reports the acquisition of stock options, which can be viewed as a positive sign of director confidence, but doesn't provide enough information to strongly indicate a positive or negative outlook.
Positives
- The acquisition of stock options by a director can be seen as a positive sign, indicating confidence in the company's future performance.
Industry Context
Stock option grants are a common form of executive compensation in the biotechnology industry, aligning the interests of management with those of shareholders.
Key Dates
| Date | Description |
|---|---|
| 06/14/2024 | Date of earliest transaction: Acquisition of 45,000 stock options. |
| 06/14/2024 | Grant date for stock options. |
| 06/17/2024 | Date of signature on the Form 4 filing. |
| 06/14/2034 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.